WG1: Antimicrobial Materials Safe-by-Design
Reaching a conceptual understanding of the mechanisms and construction of an active and sustainable coating, to adapt current and develop new coatings to meet ECHA standards.
Deliverables & Milestones:
- Database combining active ingredients and substrates for use of AMC in healthcare
- Exchange of unpublished AMC information between Action members on AMC development and application in healthcare
- Opinion paper on safe- by-design approaches for development and application of AMC
Work Group 1 Leader:
- Nuno Azevedo, Professor, Assistant Professor, LEPABE – Dep. of Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal; E: nazevedo<at>fe.up.pt
Work Group 1 Vice Leader:
- Simone Schulte, PhD, Coating Additives -Innovation Management, Evonik Resource Efficiency GmbH, Germany; E: simone.schulte<at>evonik.com,
WG2: Performance Assessment of Antimicrobial Coatings in Healthcare
Current and new antimicrobial coatings (AMC) will only either enter the healthcare market or have an impact on hygiene and hospital acquired infections if their efficacy can be shown in appropriate (field) testing. However, testing AMCs in a healthcare environment has ethical and practical issues. In order to allow proper testing of the efficacy of an AMC it is essential to know the problem that the coated material is intended to solve. In addition, the expected site of intervention (e.g. surfaces, textiles, clothing) as well as other factors (eg cleaning and disinfection, environmental conditions etc) will have an influence on the effect intended. Many (standardised) methods are available that can detect antimicrobial properties of a large diversity of materials although a much smaller sub-set are suited to examining hygienic or self disinfecting properties. It is often difficult to decide which method should be employed to explore the effect of a certain material-coating combination in a certain environment and methods must usually be modified to demonstrate effects in practice. Furthermore, none of the methods available seem to be really suitable to predict the overall efficacy on bacterial contamination in the hospital and/or care environment. This calls for guidelines related to use and/or the design of reliable tests that can be used to evaluate and compare the effect of AMCs (e.g. impact, durability, etc.).
The AMICI action members in workgroup 2 (WG2) will therefore work on the collection of current methods, both lab-based and field-based assays. They will then be ranked and benchmarked, in relation to the use of a certain assay, to enable a better understanding of their applicability to sue in examining claims made for the performance of AMCs and to help guide the development priorities for new methods.
AMICI WG 2 aims to identify appropriate testing methods / models for laboratory and field-based assays.
• Collection of current methods
– Standard and others (including publications)
– What they are used for (dental, hospital etc.)
– Durability (what approaches are used)
• Create a portfolio
– Suitability for end uses / ranking of existing methods
• Create a guidance document
The first period of the project will focus on lab-based assays and the second period on field-based assays.
- Peter D. Askew, Managing Director IMSL LTD,
WG2 Vice Leader:
- Dr. Birgit E.J. Teunissen, Business Development Manager CHILL,
We invite everyone who is experienced with the testing of antimicrobial coatings and/or other materials to either become part of the AMICI consortium and/or to share their experiences with us. For further information on WG2 Performance assessment please contact Pete Askew (link to contact info) or Birgit Teunissen (link to contact info).
WG3: Adverse effects and Risk-benefit analysis
A potential and promising weapon against bacterial growth and possibly the development of multi-drug resistant bacteria has been found in AntiMicrobial (nano)-Coatings (AMC). So far, little is known about the potential harmful effects of apllication of AMC in health-care setting, i.e. (i) the ecotoxicological risks (via various waste streams) as well as (ii) the potential induction of antimicrobial resistance (AMR). Therefore, in order to gurantee a sustainability of application of AMC, a balanced risk-benefit analysis of widespread application of
AMC is needed, to guide a ‘Safe-by-Design’ development of AMC. The focus of WP3 is on (eco)toxicological risks and possible introduction of antimicrobial resistance AMR resulting from the use of antimicrobial coatings (AMC).
The introduction of (nano)-coatings with new active components (e.g. nanosilver) along with different methods for cleaning (WG4) will cause a change in the emission of toxic agents into the environment. Active ingredients will slowly enter the ecosystem and cause exposure of human, livestock and microorganisms to low concentrations of different agents. These agents (e.g. AgNP, Ag+, CuNP, and TiO2) may cause adverse effects on organisms living in specific water and soil compartments. In addition, the slow infusion of active ingredients may induce resistance mechanisms that differs from current antibiotic driven mechanisms. The widespread introduction of such coatings therefore needs to be subjected to risk-benefit analyses. WG3 will focus on (eco) toxicological risks and the possible induction of antimicrobial resistance (AMR) resulting from the use of antimicrobial coatings (AMC).
Deliverables & Milestones
- Inventory/review on current knowledge of impact of AMCs on ecosystems
- Risk/benefit analysis based on inventory of available knowledge on (eco)toxicological aspects of AMCs and possible development of AMR to AMC
- Recommendations on further development and application of AMCs in healthcare, taking into account the risk/benefit analysis
- Expert statement on further research and policy with regard to prevention of antimicrobial resistance
- Inform regulatory bodies and analytical services on risks and benefits of AMCs in healthcare
Work Group 3 Leader:
- Anne Kahru, Head of the Lab. of Environmental Toxicology, National Institute of Chemical Physics and Biophysics, Tallinn, Estonia. Web: www.kbfi.ee. E: anne.kahru<at>kbfi.ee
Work Group 3 Vice Leader:
WG4: New Cleanning - Hygiene in Health Care Institutions
Investigate new methods of effective cleaning, additional to the use of AMCs to ensure a safe and more hygienic future.
Deliverables & Milestones
- Comparison of AMC-based cleaning systems regarding safety, efficacy, sustainability and durability to the frequently used systems in – healthcare
- Guidelines on new cleaning procedures, in compliance with and additional to the use of AMCs, for cleaning industries in healthcare.
Work Group 4 Leader:
- Dr. Martina Modic Postdoctoral researcher, Jožef Stefan Institute Department of Surface Engineering and Optoelectronics
Ljubljana, Slovenia | email@example.com | +38614773672| https://www.ijs.si/ijsw
Work Group 4 Vice Leader:
- Colum Dunne, Professor, Graduate Entry Medical School, University of Limerick, Ireland; E:colum.dunne<at>ul.ie
WG5: Communication and Dissemination
General objective of the Work Group 5 is to communicate and disseminate knowledge gathered and developed by AMICI members. In particular WG5 actions aim to:
- build and maintain the branded network of professionals
- foster learning and exchange
- rise awareness & spread the information about AMC
- communicate about project activities and relevant opportunities
- monitor and communicate the impact
Deliverables & Milestones
- Project website
- Database of experts in the field
- Organisation of meetings and events
- Participation in meetings and conferences of other networks and stakeholders
- Involvement of Framework Program policy makers to mid-term and final Action conferences
- Expansion of AMiCI network with key stakeholders including producers, suppliers and (potential) users of AMC in healthcare and organisations involved with hygiene standards
- Exchange of ECI’s between institutes of different countries and between knowledge institutes and industry
WG 5 Leader:
- Kazimierz Murzyn, Foundation Klaster LifeScience Kraków, Poland | kmurzyn<at>lifescience.pl | +48 504 106 466 | www.lifescience.pl